Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2023-02-22 Regulatory Filings
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Receipt of R&D Tax Incentive Payment 1 page 77.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 23 February 2023 regarding the receipt of an R&D Tax Incentive payment from the Australian Taxation Office for the financial year ending 30 June 2022. The content is a brief notification about the receipt of a tax refund related to R&D expenditure. It does not contain financial statements, detailed financial analysis, or management discussion. The document length is short (2237 characters) and it is an announcement of a specific event (receipt of payment). Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-02-22 English
Half Yearly Report and Accounts 28 pages 1.2MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Antisense Therapeutics Limited Appendix4D For the Half-year ended 31 December 2022' and contains detailed financial results, directors' report, auditor's review report, and comprehensive financial statements for the half-year period ending 31 December 2022. It includes profit and loss statements, cash flow, notes to financial statements, and a directors' declaration. The document is about a half-year period and contains substantive financial data and analysis, not just an announcement or summary. This matches the definition of an Interim / Quarterly Report (IR). The document length is 15,000 characters, indicating it is a full report, not a brief announcement or certification. Therefore, the correct classification is IR with high confidence. H1 2023
2023-02-21 English
Presentation at International Conference on DMD 2 pages 104.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 17 February 2023 regarding a clinical trial presentation at an international conference. It provides an overview of the ATL1102 Phase IIb Duchenne muscular dystrophy trial and details about the conference and the company's involvement. The document does not contain financial statements, detailed financial analysis, or regulatory filings. It is primarily an announcement about a presentation event and clinical trial update rather than a financial report or regulatory filing. The length is 6544 characters, which is sufficient for a detailed announcement but does not constitute a full report like an Annual Report or Interim Report. Therefore, the document fits best into the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2023-02-16 English
First approval for ATL1102 Phase IIb DMD clinical trial 2 pages 103.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 14 February 2023 from Antisense Therapeutics Limited regarding the receipt of regulatory approval to conduct a Phase IIb clinical trial for ATL1102 in Duchenne muscular dystrophy (DMD). The content focuses on the announcement of a regulatory milestone and trial initiation plans, with no financial statements, earnings data, or detailed financial analysis. It is a corporate announcement about clinical trial progress rather than a financial report or regulatory filing. The document length is 8,335 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a report publication announcement or a certification. Therefore, the document best fits the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit into other specific categories such as earnings release, capital update, or management report.
2023-02-13 English
Limb Girdle Muscular Dystrophy R2 animal study commenced 2 pages 111.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 13 February 2023 from Antisense Therapeutics Limited. It announces the commencement of a second phase animal study for a drug candidate targeting Limb Girdle Muscular Dystrophy R2. The content focuses on the study details, collaborations, disease background, and references to prior studies and patents. There are no financial statements, earnings data, or regulatory certifications. The document is a corporate announcement about a research program progress rather than a financial report, management change, or regulatory filing. It is not a report publication announcement since it contains substantive information about the study commencement and context. Therefore, the best fitting category is a general Regulatory Filing (RNS) as it is a regulatory announcement to the market about a material development in the company’s research pipeline.
2023-02-12 English
Positive outcomes in DMD combination therapy animal study 5 pages 329.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 1 February 2023 from Antisense Therapeutics Limited. It reports positive outcomes from a preclinical animal study involving combination therapy for Duchenne muscular dystrophy (DMD). The content focuses on scientific study results, muscle function endpoints, patent application filing, and ongoing research. There are no financial statements, regulatory certifications, or management discussions typical of annual or interim reports. The document is a detailed announcement of research progress and patent filing rather than a financial or governance report. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing or a report publication announcement since it contains substantive study data and analysis. The document is best classified as a Regulatory Filings (RNS) type, as it is a general regulatory announcement about research progress and patent application filed, which does not fit other specific categories.
2023-01-31 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.